Brain metastases, cancer cells that spread to the brain from the primary breast tumor, represent one of the most devastating complications in metastatic breast cancer. Despite being a significant cause of morbidity and mortality, information on their prevalence throughout the evolving course of systemic therapy remained scarce. The current study addresses this knowledge gap by investigating brain metastases prevalence at the time of metastatic diagnosis and at the start of various lines of systemic therapy, alongside treatment patterns and overall survival outcomes.

Analyzing a cohort of nearly 13,000 adult mBC patients diagnosed between 2013 and 2020, the research stratified findings based on HER2 status—a key molecular subtype that influences disease behavior and treatment responses. The nuanced differentiation between HER2-positive (HER2+) and HER2-negative (HER2−) breast cancers proved central to understanding metastasis dynamics and survival probabilities.

At initial metastatic diagnosis, the data exposed a glaring disparity: brain metastases were present in 12.5% of patients with HER2+ disease, compared to only 1.7% among HER2− patients. This early divergence underscores the aggressive nature of HER2+ breast cancers in penetrating the central nervous system, demanding heightened clinical vigilance at the outset of metastatic disease.

Intriguingly, the prevalence of brain metastases was found to amplify over the course of treatment. Among HER2+ patients who have undergone multiple lines of systemic therapy, documented brain metastases before or within the same month of a new therapy initiation rose dramatically—from 11.2% after one prior line, to 22.8% after two, and a staggering 33% by the third line. Contrastingly, in the HER2− cohort, the increase was modest, from 1.6% to 2.8% over the same treatment intervals, reflecting a more indolent progression of brain involvement.

Despite the significant burden of brain metastases, the study revealed a troubling pattern regarding treatment: only a fraction of patients with brain metastases received systemic therapies recommended by the National Comprehensive Cancer Network (NCCN) guidelines for brain involvement. Specifically, during first-line therapy, just 25% of HER2+ patients and an even smaller 12.8% of HER2− patients with brain metastases were administered such guideline-recommended regimens, highlighting a critical treatment gap in clinical practice.

This shortfall in delivering optimal systemic therapy to brain metastasis patients raises important questions about potential barriers, ranging from treatment accessibility, central nervous system drug penetration challenges, to clinicians’ therapeutic decision-making weighed against patient performance status or comorbidities. It stresses an unmet medical need to enhance both the availability and appropriateness of therapeutic options targeting brain metastases.

Survival outcomes further reflect the dire impact of brain metastases. Median overall survival from the time of metastatic diagnosis was markedly worse in patients harboring brain metastases compared to those without. HER2+ patients with brain metastases had a median survival of 24 months, versus 37 months for those without brain involvement—a significant decrement in life expectancy. The survival gap was even more pronounced in the HER2− subgroup, where median survival plummeted to 12 months from 27 months in patients without brain metastases.

These sobering survival statistics underscore the aggressive course brain metastases carve in metastatic breast cancer, particularly affecting the hematogenous spread and treatment-resistant nature of these lesions within the protective environment of the brain. They reveal the critical urgency for innovative therapeutic modalities that overcome these biological and clinical hurdles.

This comprehensive study benefits from the utility and richness of electronic health records, which provide a real-world lens into clinical practices and patient trajectories outside the confines of randomized clinical trials. Such data empower the oncology community to critically assess current treatment paradigms and outcomes, driving a patient-centered approach to care improvement.

Notably, the study’s findings elucidate the evolving natural history of brain metastases in metastatic breast cancer, emphasizing the increasing prevalence with successive lines of therapy and exposing the conspicuous underuse of guideline-recommended treatments. These insights prompt a reevaluation of routine brain metastasis screening, earlier interventions, and the integration of specialized CNS-directed systemic therapies in treatment algorithms.

Moreover, the distinct survival differences observed between HER2+ and HER2− populations highlight the heterogeneity of metastatic breast cancer and the need to tailor therapeutic strategies accordingly. HER2+ patients, while at higher risk for brain metastases, also feature emerging targeted therapies that could potentially mitigate CNS progression if effectively administered.

This study thus serves as an urgent call for the oncology research community and pharmaceutical development pipelines to prioritize the discovery and dissemination of more efficacious and brain-penetrant therapeutic agents. Additionally, it underscores the need for tailored clinical guidelines that better address the complexities of brain metastases management across molecular subtypes.

In conclusion, this seminal research provides critical real-world evidence that advances understanding of brain metastases epidemiology in metastatic breast cancer, revealing troubling prevalence increases over time and poor survival linked to CNS involvement. It spotlights a major gap in the delivery of recommended treatments and the dire need for innovations to improve outcomes for this vulnerable patient population. As brain metastases continue to pose formidable challenges, informed and targeted improvements in clinical practice and drug development remain paramount.

The findings from Varghese et al.’s cohort study chart a crucial path forward—integrating enhanced surveillance, breaking down therapeutic barriers, and utilizing precision oncology tools to combat brain metastases in metastatic breast cancer. These strides are essential to transform grim prognoses into actionable hope for thousands of patients facing the dual struggle of breast cancer and its cerebral complications.

Subject of Research: Epidemiology, treatment patterns, and survival outcomes of brain metastases in patients with metastatic breast cancer, stratified by HER2 status.

Article Title: Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer – a cohort study in US electronic health record data.

Article References: Varghese, D., Collins, J., Nordstrom, B. et al. Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer – a cohort study in US electronic health record data. BMC Cancer 25, 1475 (2025). https://doi.org/10.1186/s12885-025-14786-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14786-6

Women who carry deleterious mutations in the BRCA1 and BRCA2 genes are known to face markedly elevated lifetime risks of both breast and ovarian cancers, often prompting early preventative interventions. Clinical guidelines currently recommend that these at-risk individuals undergo risk-reducing surgeries such as BSO relatively early in adulthood—typically between ages 35 and 40 for BRCA1 carriers, and between 40 and 45 for BRCA2 carriers—to mitigate the aggressive threat ovarian cancer presents. While BSO has been widely recognized to curtail ovarian cancer incidence by approximately 80%, its overall impact on all-cause mortality, particularly in those with prior breast cancer diagnoses, alongside potential systemic side effects, had remained uncertain until now.

This uncertainty stems partly from the physiological consequences of surgically induced menopause, as the abrupt cessation of ovarian estrogen production precipitates a range of metabolic, cardiovascular, and psychological changes. Notably, hormone replacement therapy—commonly prescribed to alleviate menopausal symptoms—is often contraindicated or cautiously approached in breast cancer survivors due to concerns over hormone-sensitive tumor recurrence. Thus, evaluating BSO’s net clinical benefit in BRCA1 and BRCA2 mutation carriers with prior breast cancer is particularly challenging, rendering randomized controlled trials ethically and practically unfeasible.

Faced with this methodological impasse, the research team capitalized on the power of big data, leveraging comprehensive electronic health records curated by the National Disease Registration Service (NDRS) in NHS England. Through meticulous data linkage to genetic testing results, clinical outcomes, and longitudinal follow-up, they constructed a robust retrospective cohort comprising approximately 3,400 women known to carry BRCA1 or BRCA2 pathogenic variants and previously diagnosed with breast cancer. Of these, nearly 1,850 individuals had undergone BSO, allowing a detailed comparative survival analysis between operated and non-operated groups over a median follow-up period exceeding five years.

The study’s statistical analyses unveiled a striking reduction in the risk of death from any cause among women who chose BSO, with hazard ratios approximating 0.5, signaling a 50% lower likelihood of mortality compared to those who did not undergo the surgery. The survival advantage was even more pronounced in BRCA2 mutation carriers, exhibiting a 56% reduction in mortality risk, while BRCA1 carriers demonstrated a 38% reduction. Beyond mortality, the surgery was associated with a 40% drop in the incidence of secondary cancers, underscoring its protective effect beyond ovarian cancer prevention.

Crucially, the investigators addressed longstanding concerns regarding BSO-induced comorbidities by analyzing rates of cardiovascular disease, cerebrovascular events, and depression. Contrary to reports from general population studies that linked early oophorectomy with heightened risks of heart disease and stroke, this study found no statistically significant association between BSO and these adverse long-term outcomes within the BRCA-mutated breast cancer cohort. Furthermore, mental health outcomes did not deteriorate, alleviating fears of increased depression linked to surgical menopause in this vulnerable population.

These findings mark a pivotal advance in the clinical management of women at genetic risk for gynecological and breast cancers. As Hend Hassan, the study’s lead author and a PhD candidate in Cambridge’s Centre for Cancer Genetic Epidemiology, articulated, the results offer reassurance that the pronounced survival benefits of BSO substantially outweigh the potential menopausal side effects feared by patients and clinicians alike. This clarity empowers both patients and healthcare providers to make more informed, evidence-based decisions regarding prophylactic surgery.

However, the research also shed light on inequities in healthcare access and decision-making. The data revealed that white women were significantly more likely to receive BSO than their Black and Asian counterparts, with the latter groups having approximately half the surgery uptake rate. Additionally, socioeconomic disparities emerged, as women residing in less deprived areas underwent BSO more frequently than those from highly deprived communities. These observations highlight urgent public health needs to elucidate and address the sociocultural, economic, and systemic barriers that impede equitable delivery of life-saving interventions.

Antonis Antoniou, senior author of the study and Director of the Cancer Data-Driven Detection programme at Cambridge, emphasized that the results will transform clinical guidelines and counseling approaches. By quantifying the substantial survival benefit and alleviating fears about serious side effects, the study equips practitioners with solid scientific footing to recommend BSO confidently to eligible patients. Furthermore, the research exemplifies the immense value of integrated NHS datasets for conducting large-scale, impactful, and clinically relevant epidemiological studies.

This investigation’s innovative methodology—exploiting carefully linked, real-world health records complemented by genetic testing data—circumvents ethical constraints surrounding randomized trials and illustrates a new frontier for precision medicine research. The capacity to generate robust evidence at scale, particularly in rarer high-risk subpopulations, promises accelerated discovery and refinement of personalized preventive strategies across oncology and beyond.

Funded primarily by Cancer Research UK, with critical support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, this study not only advances scientific understanding but also aligns closely with ongoing translational efforts. The University of Cambridge’s partnership in establishing the Cambridge Cancer Research Hospital underscores a broader commitment to harnessing cutting-edge research to transform patient outcomes in the UK and internationally.

In sum, this landmark research definitively supports the recommendation of bilateral salpingo-oophorectomy for BRCA1 and BRCA2 mutation carriers with prior breast cancer, confirming significant improvements in survival and reduction in secondary cancer risk without exacerbating cardiovascular or mental health burdens. As the medical community integrates these insights into practice, the hope is to redress disparities in access and empower more women to benefit from this potentially life-saving procedure.

Subject of Research: People

Article Title: Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records

News Publication Date: 8-May-2025

Web References:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00156-1/fulltext
http://dx.doi.org/10.1016/S1470-2045(25)00156-1

References:
Hassan, H et al. Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records. Lancet Oncology; 7 May 2025; DOI: 10.1016/S1470-2045(25)00156-1

Keywords: Cancer, Breast cancer, Ovarian cancer